Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, developing precision therapies for solid tumors that aim to preserve organ function. News about AURA stock frequently centers on clinical trial milestones, regulatory designations, financing activities, and participation in healthcare and investor conferences.
A key theme in Aura’s news flow is progress with its lead candidate, bel-sar (AU-011). The company regularly reports updates on the global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, which it describes as the first registration-enabling study in this indication. Press releases also cover developments in additional ocular oncology programs, including metastases to the choroid and cancers of the ocular surface, and in non-muscle invasive bladder cancer, where Aura has shared Phase 1 data and details of an ongoing Phase 1b/2 trial.
Investors following AURA news can expect recurring coverage of regulatory interactions, such as Orphan Drug and Fast Track designations for bel-sar, as well as financial updates through quarterly and annual results furnished via Form 8-K. Aura’s announcements also include public offering details, cash runway commentary, and information about patent applications for new formulations of bel-sar in urologic oncology.
In addition, Aura frequently announces participation in healthcare and life sciences conferences, fireside chats, and investor events, where senior management discusses the company’s pipeline and strategy. For anyone tracking AURA, this news page provides a centralized view of Aura Biosciences’ clinical progress, corporate developments, and capital markets activity over time.
Aura Biosciences (Nasdaq: AURA) closed an underwritten public offering on May 5, 2026, selling 46,099,650 common shares (including full exercise of the underwriters' option) and pre-funded warrants to purchase up to 3,800,000 shares.
Securities sold at $6.00 per share and $5.99999 per pre-funded warrant, producing approximately $299.4 million gross proceeds before underwriting discounts, commissions and offering expenses.
Aura Biosciences (Nasdaq: AURA) priced a public offering to sell 39,591,000 shares and pre-funded warrants for up to 3,800,000 shares, at $6.00 and $5.99999 respectively, with gross proceeds expected of $260.3 million. Aura granted underwriters a 30-day option for up to 6,508,650 additional shares. The offering is expected to close on or about May 5, 2026. Aura intends to use approximately $205.1 million of net proceeds, plus existing cash, to advance clinical programs and registration-enabling activities for bel-sar, and to repurchase up to 6,922,870 shares from Matrix at $5.64 per share.
Aura Biosciences (Nasdaq: AURA) launched an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common stock. Aura also intends to give underwriters a 30-day option to buy up to an additional 15% of the offering.
The offering is subject to market conditions and will be made from a Form S-3 shelf registration declared effective April 5, 2024; final terms will appear in a prospectus supplement filed with the SEC.
Aura Biosciences (NASDAQ: AURA) appointed Natalie Holles as CEO, President and board member effective April 30, 2026, replacing founder Elisabet de los Pinos. The company reports its Phase 3 CoMpass trial of belzupacap sarotalocan for early choroidal melanoma is nearing enrollment completion with 86 patients enrolled and >25 more scheduled or identified through May 2026. Aura reiterates enrollment completion by mid-2026 and topline CoMpass data in H2 2027.
Aura Biosciences (NASDAQ: AURA) reported Q4 and full-year 2025 results and program updates on March 30, 2026.
Key points: CoMpass Phase 3 enrollment now expected complete by mid-2026 with topline data in 2H 2027; Phase 1b/2 NMIBC initial 3-month data expected mid-2026; new formulation achieved 12-month stability for non-ocular solid tumors and a patent application was filed; cash and marketable securities totaled $144.2M, funding operations into Q1 2027.
Aura Biosciences (NASDAQ: AURA) said senior management will participate in three investor conferences in March 2026 with live fireside chats and webcasts. Events include TD Cowen on March 4, Leerink Partners on March 10, and Citizens Life Sciences on March 11.
Live webcasts will be available on the company's Investors & Media page and replays will be archived for 90 days after each presentation.
Aura Biosciences (NASDAQ: AURA) will participate in the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025. CEO Elisabet de los Pinos, PhD, will appear in a fireside chat at 10:50 a.m. ET. A live webcast will be available on the company’s Investors & Media Events & Presentations page and a replay will be archived for 90 days following the presentation.
This presentation provides an investor update opportunity with company leadership and a public webcast for remote access.
Aura Biosciences (NASDAQ: AURA) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company now expects to complete enrollment in its global Phase 3 CoMpass trial in 2026 with topline data for the 15-month primary endpoint in Q4 2027. The Phase 1b/2 NMIBC trial remains on track with initial three-month data expected in mid-2026. Phase 1 immune-profiling showed de novo mature tertiary lymphoid structures in 3/5 patients and increases in NK and T-cell densities (NK up to 40x, CD4+ cytolytic up to 7x).
Financials: cash and marketable securities of $161.9M as of Sept 30, 2025, funding operations into the first half of 2027. R&D expense rose to $22.2M (Q3 2025) and net loss was $26.1M for the quarter.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's CEO, Elisabet de los Pinos, PhD, will deliver a presentation on September 10, 2025, at 11:00 a.m. ET. Investors can access the live webcast through Aura's investor relations website, where it will remain available for replay for 90 days after the presentation.
Aura Biosciences (NASDAQ: AURA) reported Q2 2025 financial results and clinical progress updates. The company strengthened its financial position with a $75 million equity financing, extending cash runway into H1 2027. Current cash position stands at $177.3 million.
Key clinical developments include the ongoing global Phase 3 CoMpass trial in early choroidal melanoma, with over 240 patients registered for pre-screening and expected completion by end of 2025. The company is also advancing a Phase 1b/2 trial in non-muscle invasive bladder cancer (NMIBC) and expanding its ocular oncology program to include metastases to the choroid and cancers of the ocular surface.
Q2 2025 financials showed increased R&D expenses of $22.9 million (vs $16.9M in Q2 2024) and slightly decreased G&A expenses of $5.7 million (vs $5.9M in Q2 2024). Net loss widened to $27.0 million compared to $20.3 million in Q2 2024.